NASDAQ:MRUSMerus Stock Price, Forecast & News

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRUS stock has decreased by 9.0% and is now trading at $13.23.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merus.

Merus is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020.
View our earnings forecast for Merus.

Merus NV (NASDAQ:MRUS) announced its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.14. The biotechnology company earned $6.30 million during the quarter, compared to the consensus estimate of $8.05 million. Merus had a negative net margin of 225.21% and a negative return on equity of 62.96%.
View Merus' earnings history.

3 equities research analysts have issued 12-month price targets for Merus' shares. Their forecasts range from $16.00 to $23.00. On average, they expect Merus' stock price to reach $20.67 in the next year. This suggests a possible upside of 56.2% from the stock's current price.
View analysts' price targets for Merus.

News coverage about MRUS stock has trended negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merus earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Merus.

Merus saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 288,300 shares, an increase of 14.1% from the June 15th total of 252,600 shares. Based on an average daily volume of 164,600 shares, the short-interest ratio is presently 1.8 days. Approximately 1.5% of the company's shares are short sold.
View Merus' Current Options Chain.

Some companies that are related to Merus include Madrigal Pharmaceuticals (MDGL), Dicerna Pharmaceuticals (DRNA), Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), MacroGenics (MGNX), Akebia Therapeutics (AKBA), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Amneal Pharmaceuticals (AMRX), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), ZEALAND PHARMA/S (ZEAL), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI) and Innoviva (INVA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE).

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.66%), Alps Advisors Inc. (0.14%) and Swiss National Bank (0.12%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology.
View institutional ownership trends for Merus.

MRUS stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and Alps Advisors Inc..
View insider buying and selling activity for Merus.

MRUS stock was acquired by a variety of institutional investors in the last quarter, including Swiss National Bank. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Merus.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $13.23.

Merus has a market capitalization of $384.20 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

The official website for Merus is www.merus.nl.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]